Diabetes management can vary greatly from person-to-person, creating multiple market segments based on clinical needs, personal preferences and affordability. Our strategy is to redefine global leadership in insulin delivery solutions through commercial excellence, patient-first reimbursement choices, and a differentiated device portfolio. We strive to offer all people with insulin-dependent diabetes flexibility and choice in their intelligent insulin delivery systems, through our portfolio of market-leading pumps, applications, and insights that improve outcomes and reduce the daily burden of living with diabetes.
In support of this strategy, we continue to drive innovation in our Tandem pump platforms. In November 2026, the Tandem Mobi insulin pump was cleared for tubeless and tubed insulin infusion options, making it the only pump that offers users the flexibility to choose the wear option that best meets their needs. In addition, our pipeline also includes a next-generation Mobi patch pump that leverages the technology acquired with the Sigi Patch Pump to deliver further miniaturization. Our development efforts also include extended-wear infusion set technology, dual glucose-ketone sensor integration, and algorithm advancement in pursuit of offering fully closed loop technology.
Note: The information on this page discusses products that may not be approved by the FDA. This information is intended for people researching the company, and is updated in conjunction with public announcements about our product innovations. All dates and information are as of November 5, 2026. Tandem Diabetes Care undertakes no obligation to update or review any forward-looking information below based on new information, future events, or other factors.